Cyrys S, Daut J
Physiologisches Institut, Technischen Universität München, Munich, Germany.
Cardiovasc Res. 1994 Jun;28(6):888-93. doi: 10.1093/cvr/28.6.888.
The aim was to obtain an estimate of the affinity of glibenclamide binding to ATP sensitive potassium channels of coronary smooth muscle cells in the intact guinea pig heart, in order to assess possible cardiovascular risks for diabetic patients receiving sulphonylurea drugs.
The arrested isolated perfused heart was used as a bioassay for KATP channels in coronary resistance vessels. The decrease of coronary perfusion pressure induced by hypoxia and by various concentrations of the potassium channel opener levcromakalim was measured and the inhibitory effect of glibenclamide on hypoxic and drug induced vasodilatation was analysed.
The delay between application of hypoxic solution and half maximum vasodilatation was on average 105(SEM 4) s. It was increased by 17.6(2.0) s in the presence of 5 nM glibenclamide. The dose-response curve of the effects of levcromakalim on coronary perfusion pressure was shifted to the right in the presence of 20 nM to 1 microM glibenclamide. The concentrations of levcromakalim required to produce half maximum vasodilatation in the presence and absence of glibenclamide were determined, and the data were analysed using a Schild plot. The measured concentration ratios could be fitted by a straight line with a slope of 0.93(SD 0.04), which was not significantly different from 1. This is consistent with competitive inhibition of the vasodilator effects of levcromakalim by glibenclamide. The apparent dissociation constant of glibenclamide binding to KATP channels in coronary smooth muscle cells was 35 nM.
The KATP channels in coronary resistance arteries are almost as sensitive to inhibition by glibenclamide as the KATP channels in pancreatic beta cells. It is likely that the plasma concentrations reached after oral ingestion of glibenclamide may inhibit a fraction of the KATP channels in coronary smooth muscle cells and thus impair hypoxic dilatation of coronary resistance arteries.
旨在获得格列本脲与完整豚鼠心脏冠状动脉平滑肌细胞上ATP敏感性钾通道结合亲和力的估计值,以评估接受磺脲类药物治疗的糖尿病患者可能存在的心血管风险。
将停搏的离体灌注心脏用作冠状动脉阻力血管中KATP通道的生物测定法。测量缺氧和不同浓度钾通道开放剂左旋克罗卡林诱导的冠状动脉灌注压降低,并分析格列本脲对缺氧和药物诱导的血管舒张的抑制作用。
应用缺氧溶液至最大血管舒张一半时的延迟平均为105(标准误4)秒。在存在5 nM格列本脲的情况下,延迟增加了17.6(2.0)秒。在存在20 nM至1 μM格列本脲的情况下,左旋克罗卡林对冠状动脉灌注压的剂量反应曲线向右移动。确定了在存在和不存在格列本脲的情况下产生最大血管舒张一半所需的左旋克罗卡林浓度,并使用Schild图分析数据。测得的浓度比可以用斜率为0.93(标准差0.04)的直线拟合,该斜率与1无显著差异。这与格列本脲对左旋克罗卡林血管舒张作用的竞争性抑制一致。格列本脲与冠状动脉平滑肌细胞中KATP通道结合的表观解离常数为35 nM。
冠状动脉阻力动脉中的KATP通道对格列本脲抑制的敏感性几乎与胰腺β细胞中的KATP通道相同。口服格列本脲后达到的血浆浓度可能会抑制冠状动脉平滑肌细胞中的一部分KATP通道,从而损害冠状动脉阻力动脉的缺氧舒张。